Off-Label Promotion: FDA Court Filing Says It Must Retain Enforcement Flexibility, Citing Harms From Premarin And ESAs
Executive Summary
FDA adamantly rejected Allergan's proposals to loosen restrictions on off-label drug promotion in a further response to Allergan's suit against the agency
You may also be interested in...
Allergan's Off-Label Suit Against FDA Will Continue Despite Botox Approval For Spasticity
Allergan is continuing to press for a court order that FDA's restrictions on off-label promotion are unconstitutional; a court hearing in the case is set for April 26.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials